Full-Time

Senior Validation Engineer

Posted on 2/21/2026

PCI Pharma Services

PCI Pharma Services

1-10 employees

Pharmaceutical packaging and contract services

Compensation Overview

$97.3k - $107k/yr

Rockford, IL, USA

In Person

Category
QA & Testing (1)
Required Skills
Minitab
Requirements
  • Bachelor’s degree in Engineering, Life Sciences, or a related technical discipline; advanced degree preferred.
  • Minimum of 5–8 years of validation experience in the medical device, pharmaceutical, or biotech industry.
  • Strong knowledge of FDA regulations, ISO 13485, ISO 14971, and GAMP 5 principles.
  • Hands-on experience with equipment and process validation on assembly lines (manual, semi-automated, or fully automated).
  • Proficient in risk management and statistical tools (e.g., Minitab, JMP).
  • Excellent technical writing and communication skills.
  • Ability to manage multiple projects and timelines in a dynamic manufacturing environment.
Responsibilities
  • Lead and execute validation lifecycle activities including IQ/OQ/PQ for manufacturing equipment, utilities, and automated assembly lines.
  • Develop and execute validation master plans, protocols, and reports in compliance with internal procedures and regulatory expectations.
  • Provide validation support for process changes, new product introductions (NPIs), and customer tech transfers.
  • Apply risk-based approaches (e.g., per ISO 14971) to validation strategy and justification.
  • Utilize statistical methods to define sampling plans and acceptance criteria for validation studies.
  • Support cleaning validation and verification activities for equipment used in medical device production.
  • Collaborate with cross-functional teams, including Manufacturing, Quality, Engineering, and Regulatory Affairs.
  • Review and approve equipment specifications, process FMEAs, URS, and validation documentation.
  • Conduct gap assessments and remediation planning for existing validation documentation when required.
  • Ensure all validation activities meet the standards set by FDA 21 CFR Part 820, ISO 13485, and customer requirements.
  • Support regulatory and customer audits as the validation SME.
Desired Qualifications
  • Experience with vision systems, leak testers, ultrasonic welding, and other medical device assembly technologies.
  • Familiarity with software validation and PLC-based control systems.
  • Six Sigma certification or formal training in statistical process control (SPC).

PCI Pharma Services offers end-to-end pharmaceutical packaging and related services, including Folding Cartons, Labels, Contract Packaging, Clinical Services, and Brand Protection. It serves as a one-stop source for healthcare product developers and manufacturers, handling carton and label production, packaging operations, clinical services, and brand protection under one roof. The company stands out with eight decades of experience, strict cGMP and ISO compliance, lean manufacturing, ongoing R&D, and comprehensive employee training, security, hygiene, and inspection practices. Its goal is to be a trusted, end-to-end packaging partner that delivers reliable, compliant, and scalable packaging solutions, so clients can focus on their core business.

Company Size

1-10

Company Stage

Debt Financing

Total Funding

$4B

Headquarters

Burlington, Canada

Founded

1971

Simplify Jobs

Simplify's Take

What believers are saying

  • GLP-1 surge drives demand for PCI's prefilled syringes and autoinjectors.
  • Oncology-CNS pipelines favor PCI's patient-centric drug-device combinations.
  • Bain Capital's $10B valuation fuels $1B capacity expansions through 2028.

What critics are saying

  • San Diego isolator line delays to H1 2028 cede contracts to Lonza.
  • Novo Nordisk's Catalent acquisition slashes external CDMO fill-finish availability.
  • PE backers force divestitures if biotech funding dries post-2025.

What makes PCI Pharma Services unique

  • PCI integrates sterile fill-finish with drug-device assembly for end-to-end injectables.
  • Ajinomoto Althea acquisition adds rare US high-potent ADC sterile filling expertise.
  • AVI systems inspect 75 million vials annually, scaling quality without bottlenecks.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Paid Vacation

401(k) Retirement Plan

Health Savings Account/Flexible Spending Account

Company News

BioProcess International
Aug 15th, 2025
Building a better facility: BPI tours PCI manufacturing plant in Bedford

On the last day of June 2025's BIO conference in Boston, Massachusetts, contract development and manufacturing organization (CDMO) PCI Pharma Services bused a crowd of delegates to its manufacturing site in Bedford, New Hampshire where it hosted a tour of its 50,000 square-foot expansion.

Montgomery County
Jul 24th, 2025
PCI Pharma Services Valued at $10B

PCI Pharma Services in Northeast Philadelphia has received a multibillion-dollar investment from Bain Capital and Kohlberg, valuing the company at $10 billion. Kohlberg had previously invested in PCI, while Bain is a new investor. The investment will help PCI expand its services and geographic reach. The company currently operates 38 sites across seven countries and employs over 7,500 people.

JD Supra
Jul 16th, 2025
Healthcare & Life Sciences Private Equity Deal Tracker: Bain Capital and Kohlberg Invest in PCI Pharma

Healthcare & life sciences Private Equity deal tracker: Bain Capital and Kohlberg invest in PCI Pharma.

FinSMEs
Jul 15th, 2025
PCI Pharma Services Receives Investment from Mubadala, Bain Capital, and Kohlberg

PCI Pharma, a Philadelphia, PA-based contract development and manufacturing organization (CDMO) focused on biotherapies, received an investment from Bain Capital, Kohlberg, and Mubadala Investment Company.

MarketScreener
Jul 14th, 2025
PCI Pharma Services receives new funding

PCI Pharma Services announced it received a new round of funding on July 14, 2025. The funding was co-led by new investor Bain Capital, LP, and returning investor Kohlberg & Company, L.L.C. Additional participation came from returning investors Mubadala Investment Company PJSC and Partners Group Holding AG.

INACTIVE